DavidJFitzgeraldDOFACP, FCCP

PubMed

• Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.
  Weiss, E.,Sarnovsky, R.,Ho, M.,Arons, E.,Kreitman, R.,Angelus, E.,Antignani, A.,FitzGerald, D.> ;Antib Ther. 2019 Feb 26
• Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up.
  Kreitman, R. J.,Tallman, M. S.,Robak, T.,Coutre, S.,Wilson, W. H.,Stetler-Stevenson, M.,FitzGerald, D. J.,Santiago, L.,Gao, G.,Lanasa, M. C.,Pastan, I.> ;Blood. 2018 Mar 01
• Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity.
  Pasetto, M.,Antignani, A.,Ormanoglu, P.,Buehler, E.,Guha, R.,Pastan, I.,Martin, S. E.,FitzGerald, D. J.> ;Proc. Natl. Acad. Sci. U.S.A.. 2015 Feb 26
• Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.
  Onda, M.,Ghoreschi, K.,Steward-Tharp, S.,Thomas, C.,O'Shea, J. J.,Pastan, I. H.,FitzGerald, D. J.> ;J. Immunol.. 2014 Jun 04
• ABT-737 Promotes the Dislocation of ER Luminal Proteins to the Cytosol, Including Pseudomonas Exotoxin.
  Antignani, A.,Sarnovsky, R.,FitzGerald, D. J.> ;Mol. Cancer Ther.. 2014 Apr 18
• Immunotoxins for leukemia.
  Wayne, A. S.,Fitzgerald, D. J.,Kreitman, R. J.,Pastan, I.> ;Blood. 2014 Mar 01
• Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors.
  Liu, X. F.,Xiang, L.,Fitzgerald, D. J.,Pastan, I.> ;Mol. Cancer Ther.. 2013 Oct 23
• The insulin receptor negatively regulates the action of pseudomonas toxin-based immunotoxins and native pseudomonas toxin.
  Liu, X. F.,Fitzgerald, D. J.,Pastan, I.> ;Cancer Res.. 2013 Apr 1
• Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.
  Mattoo, A. R.,FitzGerald, D. J.> ;Int J Cancer. 2013 Feb 15
• Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
  Fitzgerald, D.J., Wayne, A.S., Kreitman, R.J., Pastan, I.> ;Cancer Res. 2011 Oct 15
• Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
  Fitzgerald, D. J.,Moskatel, E.,Ben-Josef, G.,Traini, R.,Tendler, T.,Sharma, A.,Antignani, A.,Mussai, F.,Wayne, A.,Kreitman, R. J.,Pastan, I.> ;Leuk. Lymphoma. 2011 May 27
• Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1.
  Du, X., Youle, R.J., FitzGerald, D.J., Pastan, I.> ;Mol Cell Biol. 2010 Jul
• ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
  Traini, R., Ben-Josef, G., Pastrana, D.V., Moskatel, E., Sharma, A.K., Antignani, A., Fitzgerald, D.J.> ;Mol Cancer Ther. 2010 Jul
• Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
  Wayne, A.S., Kreitman, R.J., Findley, H.W., Lew, G., Delbrook, C., Steinberg, S.M., Stetler-Stevenson, M., Fitzgerald, D.J., Pastan, I.> ;Clin Cancer Res. 2010 Mar 15
• Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
  Kreitman, R.J., Hassan, R., Fitzgerald, D.J., Pastan, I.> ;Clin Cancer Res. 2009-08-15
• A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
  Weldon, J.E., Xiang, L., Chertov, O., Margulies, I., Kreitman, R.J., FitzGerald, D.J., Pastan, I.> ;Blood. 2009-04-16
• Proteolytic cleavage of a C-terminal prosequence, leading to autoprocessing at the N Terminus, activates leucine aminopeptidase from Pseudomonas aeruginosa.
  Sarnovsky, R., Rea, J., Makowski, M., Hertle, R., Kelly, C., Antignani, A., Pastrana, D.V., Fitzgerald, D.J.> ;J Biol Chem. 2009-04-10
• Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
  Du, X., Beers, R., Fitzgerald, D.J., Pastan, I.> ;Cancer Res. 2008 Aug 1
• Immunotoxin treatment of cancer.
  Pastan, I., Hassan, R., FitzGerald, D.J., Kreitman, R.J.> ;Annu Rev Med. 2007
• Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
  Onda, M., Nagata, S., FitzGerald, D.J., Beers, R., Fisher, R.J., Vincent, J.J., Lee, B., Nakamura, M., Hwang, J., Kreitman, R.J., Hassan, R., Pastan, I.> ;J Immunol. 2006 Dec 15
• A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxin.
  Pastrana, D.V., FitzGerald, D.J.> ;Anal Biochem. 2006 Jun 15
• Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cells.
  Hsieh, J.C., Tham, D.M., Feng, W., Huang, F., Embaie, S., Liu, K., Dean, D., Hertle, R., Fitzgerald, D.J., Mrsny, R.J.> ;Infect Immun. 2005 Nov
• Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis.
  Wilderman, P.J., Sowa, N.A., FitzGerald, D.J., FitzGerald, P.C., Gottesman, S., Ochsner, U.A., Vasil, M.L.> ;Proc Natl Acad Sci U S A. 2004 Jun 29
• Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P.
  Mattoo, A. R.,Pastan, I.,Fitzgerald, D.> ;PLoS ONE. 2013 Oct 17
• Immunotoxins: the role of the toxin.
  Antignani, A.,Fitzgerald, D.> ;Toxins (Basel). 2013
• Join now to see all